WashU Medicine researchers designed a cellular immunotherapy that turns astrocytes (green), a type of cell in the brain, into super cleaners that sweep away Alzheimer’s-related proteins. With this new feature, the cells successfully reduced the amount of harmful amyloid beta plaques (blue) in the brains of mice.

The new generation of Alzheimer’s disease drugs — the first proven to change the course of the disease — typically extend independent living for patients by 10 months. Called monoclonal antibodies, they reduce the accumulations of a harmful protein, amyloid, in the brain and require high-dose, once- or twice-monthly infusions of the medication.

See the article HERE